Sarepta Therapeutics (SRPT) Granted FDA Accelerated Approval for Eteplirsen
Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.
Sarepta Therapeutics (NASDAQ: SRPT) surges higher on FDA approval for eteplirsen
Letter from FDA
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Sarepta Therapeutics (SRPT) Doses First Patient in SRP-4045, SRP-4053 Phase 3 Trial
- Sarepta's (SRPT) Exondys gets broad coverage from Cigna (CI) - Bloomberg
- Intra-Cellular Therapies (ITCI) Announces ITI-007 Phase 3 Missed Primary Endpoint in Schizophrenia
Create E-mail Alert Related CategoriesFDA, Hot FDA News, Management Changes, Trader Talk
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!